Papaverine - instructions for use, dose, side effects, contraindications

Spasmolytic agent, has antihypertensive effect. Inhibits phosphodiesterase, causes accumulation in the cell of cyclic adenosine monophosphate and a decrease in the calcium content; reduces tone and relaxes the smooth muscles of internal organs (gastrointestinal tract, respiratory and genitourinary system) and vessels. In large doses reduces the excitability of the heart muscle and slows intracardiac conduction. The effect on the central nervous system is poorly expressed (in large doses a sedative effect is exerted).

Pharmacokinetics:Absorption is high. Bioavailability on average - 54%. The connection with plasma proteins is 90%. It is well distributed in tissues, penetrates through the histohematetic barriers. Metabolised in the liver. Half-life is 0.5-2 hours. It is excreted by the kidneys in the form of metabolites. Completely removed from the blood during hemodialysis.

Indications:

Spasm of smooth muscles: abdominal cavity organs (cholecystitis, pilorospasm, spastic colitis); renal colic, peripheral vessels (endarteritis); vessels of the brain; heart (stenocardia - as part of complex therapy); bronchospasm.

Contraindications:

Hypersensitivity, atrioventricular blockade, glaucoma, severe hepatic insufficiency, elderly age (risk of hyperthermia), children under 10 years (for this dosage form).

Carefully:

States after cerebrospinal trauma, chronic renal failure, adrenal insufficiency, hypothyroidism, prostatic hyperplasia, supraventricular tachycardia, shock states, pregnancy, lactation (safety not established).

Dosing and Administration:

Inside. Adults 40-60 mg 3-4 times a day.The highest single dose is 200 mg, the daily dose is 600 mg.

Children older than 10 years of 20 mg 3-4 times a day. Children under 10 years of age are recommended to take children's forms of the drug.

Side effects:

Allergic reactions, atrioventricular blockade, ventricular extrasystole, lowering of arterial pressure, constipation, drowsiness, increased activity of "liver" transaminases, eosinophilia.

Overdose:

Symptoms: diplopia, weakness, lowering blood pressure, drowsiness.

Treatment: symptomatic (maintenance of arterial pressure).

Interaction:

Papaverine reduces the antiparkinsonian effect of levodopa and the hypotensive effect of the methyzopa.

In combination with barbiturates, the spasmolytic effect of papaverine is enhanced.

When combined with tricyclic antidepressants, procainamide, reserpine, quinidine, an increase in the hypotensive effect of papaverine is possible.

Special instructions:

During the treatment period, ethanol intake should be excluded.

The vasodilating effect of papaverine is reduced by smoking.

When appointing Papaverine diabetic patients should be aware that as auxiliaries in the tablet contains sucrose.

Form release / dosage:

Tablets of 40 mg.

Packaging:

For 10 tablets in a contour mesh package or 10 tablets in a contour non-jawed package.

Contour non-cellular packages, together with an equal number of instructions for use, are placed directly in the group package.

1 or 3 contour-cell or non-jawed packages together with the instruction for use are placed in a pack of cardboard.

Storage conditions:

At a temperature of no higher than 25 ° C.

Keep out of the reach of children.

Shelf life:

5 years. Do not use after the time specified on the package.

Terms of leave from pharmacies:Without recipe

Registration number:P N003915 / 01

Date of registration:16.11.2009

The owner of the registration certificate:PHARMSTANDART-TOMSKHIMFARM, OJSC PHARMSTANDART-TOMSKHIMFARM, OJSC Russia

Manufacturer: & nbsp

PHARMSTANDART-TOMSKHIMFARM, OJSC Russia

Information update date: & nbsp21.08.2015

Illustrated instructions

Instructions

Papaverine (Papaverine)